Bayesian designs with frequentist and Bayesian error rate considerations

Statistical Methods in Medical Research

Volumn 14, Issue 5, 2005, Pages 445-456

  Wang, You Gan ^a,e   Leung, Denis H Y ^b   Li, Ming ^c   Tan, Say Beng ^d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE MANAGEMENT UNIVERSITY   (Singapore)

^c AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^d DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^e CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE;

ANALYTICAL ERROR; BAYES THEOREM; CANCER PATIENT; CLINICAL STUDY; CLINICAL TRIAL; HUMAN; MATHEMATICAL COMPUTING; NASOPHARYNX CARCINOMA; PHASE 2 CLINICAL TRIAL; PROBABILITY; REVIEW;

BAYES THEOREM; BIAS (EPIDEMIOLOGY); CLINICAL TRIALS, PHASE II; HUMANS; MODELS, STATISTICAL; RESEARCH DESIGN; SINGAPORE;

EID: 27144540579     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1191/0962280205sm410oa     Document Type: Review

References (12)

1. Mariani L, Marubini E. Design and analysis of phase II cancer trials: a review of statistical methods and guidelines for medical researchers. International Statistical Review 1996; 64: 61-88.
2. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989; 10 (1): 1-10.
3. Timothy Chen T. Optimal three-stage designs for phase II cancer clinical trials. Statistics in Medicine 1997; 16: 2701-11.
4. Gittins JC, Pezeshk H. How large should a clinical trial be? Journal of the Royal Statistical Society D - The Statistician 2000; 49: 177-87.
5. Gittins JC, Pezeshk H. A behavioral Bayes method for determining the size of a clinical trial. Drug Information Journal 2000; 34: 355-63.
6. Lindley DV. The choice of sample size. Journal of the Royal Statistical Society D - The Statistician 1997; 46: 129-38.
7. Stallard N. Sample size determination for phase II clinical trials based on Bayesian decision theory. Biometrics 1998; 54: 279-94.
8. Wang YG, Leung DH. An optimal sequential design for screening trials. Biometrics 1998; 54: 245-52.
9. Heitjan DF. Bayesian interim analysis of phase II cancer clinical trials. Statistics in Medicine 1997; 16: 1791-1802.
10. Tan SB, Machin D. Bayesian two-stage designs for phase II clinical trials. Statistics in Medicine 2002; 21: 1991-2002.
11. Lee SJ, Zelen M. Clinical trials and sample size considerations: another perspective (with discussion). Statistical Science 2000; 15: 95-110.
12. Foo KF, Tan EH, Leong SS, Wee JTS, Tan T, Fong KW, Koh L, Tai BC, Lian LG, Machin D. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Annals of Oncology 2002; 13: 150-6.